Morgan Stanley Changes Ratings on RCUS, NRIX, IOBT
Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects.
/ 2 items
Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects.
IO Biotech won't submit its Cylembio cancer vaccine application after the FDA recommended against it due to trial results narrowly missing significance. IOBT will plan a new study and cut 50% of staff to save cash.